The Manufacturers Life Insurance Company Has $913,000 Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

The Manufacturers Life Insurance Company lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 25,241 shares of the specialty pharmaceutical company’s stock after selling 797 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Supernus Pharmaceuticals were worth $913,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Eversept Partners LP acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth $3,818,000. Tower Research Capital LLC TRC increased its holdings in Supernus Pharmaceuticals by 39.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,163 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 889 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Supernus Pharmaceuticals by 4.7% during the 4th quarter. MetLife Investment Management LLC now owns 30,822 shares of the specialty pharmaceutical company’s stock worth $1,115,000 after purchasing an additional 1,394 shares in the last quarter. Epoch Investment Partners Inc. increased its holdings in Supernus Pharmaceuticals by 59.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 85,691 shares of the specialty pharmaceutical company’s stock worth $3,099,000 after purchasing an additional 31,957 shares in the last quarter. Finally, Alpha DNA Investment Management LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter worth about $442,000.

Analysts Set New Price Targets

A number of research firms have issued reports on SUPN. StockNews.com cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Down 2.3%

SUPN stock opened at $31.54 on Thursday. The stock has a 50-day moving average price of $31.86 and a two-hundred day moving average price of $34.85. The stock has a market cap of $1.77 billion, a PE ratio of 29.48 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.